Sagent Pharmaceuticals is introducing Zyogreen (indocyanine green [ICG]) injection to the U.S. commercial market for use in fluorescence-guided procedures and diagnostic imaging.
Notably: This launch reportedly marks the first for a ready-to-use (RTU) ICG injection with regulatory approval in the country.
Definitely noteworthy. But first, let’s talk about Sagent.
Operating out of Schaumburg, Illinois, the generic and specialty pharmaceuticals provider offers a range of product types (prefilled syringes [PFS], premixed bags, vials, and prefilled bags) for an array of therapeutic categories—including ophthalmic care.
- Get a look at its product portfolio.
And in (relatively) recent product news: Our last coverage on Sagent was its September 2025 launch of travoprost ophthalmic solution, USP 0.0004%.
… and now to this newest launch.
What it is: Zyogereen is an optical imaging agent intended for intravenous (IV) or interstitial use. Its indication is for:
- Fluorescence imaging of:
- vessels (micro and macro-vasculature), blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries—including general minimally-invasive surgical procedures—in adults and pediatric patients
- Extrahepatic biliary ducts in adults and pediatric patients from birth to less than 1 year of age and age 6+
- Lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer
- Ophthalmic angiography in adults and pediatric patients
What are the recommended dosages for these indications?
Zylogreen is supplied as a sterile RTU solution, with each injection containing 25 mg per 10 mL (2.5 mg per mL) of ICG packaged in a single-dose ampule.
The indication-based dosages, per its prescribing information (PI):
- For visualization of vessels, blood flow, and tissue perfusion
- 0.15 mg/kg for pediatric patients (< 1 month of age)
- 1.25 mg to 5 mg for patients (aged 1 month or older)
See here for its other (non-ophthalmic) indication dosages.
So how does it compare to conventional ICG products?
Those products are typically supplied as a lyophilized powder and require reconstitution (in which liquid is added to return it to a liquid state) prior to administration.
As we mentioned earlier, Zylogreen is supplied as a sterile solution—and requires no reconstitution.
Click here for a closer look at this difference.
And where does this fit in Sagent’s portfolio?
It’s actually the company’s second Provepharm dye to hit the U.S. market; the FDA-approved Bludigo (indigotindisulfonate sodium injection) was introduced in 2022.
- For context: Developed by the French-based medical and diagnostic dye pharma company of the same name, Provepharm dyes are high-purity, RTU medical dyes. See here for their uses.
And if you’re wondering how Provepharm fits into this: Sagent is marketing and distributing Zyogreen across the United States as part of an agreement with Provepharm.
Got it. So what safety precautions should be taken with Zyogreen?
The ICG injection is contraindicated in patients with a history of ICG hypersensitivity.
As for warnings and precautions—see here (Section 5) for those.
Among the most common adverse reactions associated with use: anaphylaxis (also a result of that aforementioned ICG sensitivity) and urticaria.
All that’s left to ask is: Where can clinicians find this?
Zylogreen is currently available through Sagent’s nationwide distribution network.
Contact a representative here.